Interstitial lung disease in polymyositis and dermatomyositis;Pneumopathie interstitielle au cours des polymyosites et des dermatomyosites

Revue de Medecine Interne

Volumn 22, Issue 11, 2001, Pages 1083-1096

  Marie, I ^a   Dominique, S ^b   Remy Jardin M ^c   Hatron, P Y ^c   Hachulla, E ^c  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Course; Dermatomyositis; Diagnosis; Interstitial lung disease; Polymyositis; Therapy

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; TACROLIMUS;

BRONCHIOLITIS; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE COURSE; DISEASE MARKER; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; ONSET AGE; OUTCOMES RESEARCH; POLYMYOSITIS; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; THORAX RADIOGRAPHY;

EID: 0035177916     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(01)00473-8     Document Type: Short Survey

References (95)

1. Dermatomyositis
2. Influence of age on characteristics of polymyositis and dermatomyositis in adults
3. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis
4. Inflammatory myopathies
5. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis
6. Pulmonary disease in polymyositis/dermatomyositis
7. Interstitial pneumonitis in association with polymyositis and dermatomyositis
8. Pulmonary involvement in polymyositis and in dermatomyositis
9. Interstitial lung disease in polymyositis and dermatomyositis: Analysis of six cases and review of the literature
10. Pulmonary and cardiac manifestations of polymyositis-dermatomyositis
11. The lung in polymyositis
12. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings
13. Polymyositis presenting with respiratory failure
14. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement
15. Three types of pulmonary involvement in polymyositis
16. Pulmonary disease in polymyositis/dermatomyositis: A clinicopathological analysis of 65 autopsy cases
17. Dermatomyositis with subclinical myositis and spontaneous pneumomediastinum with pneumothorax: Case report and review of the literature
18. Interstitial lung disease in polymyositis and dermatomyositis
19. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: Prediction and treatment with cyclosporine
20. Polymyositis and diffuse interstitial lung disease. A review of the pulmonary histopathologic findings
21. Interstitial lung disease in polymyositis and dermatomyositis
22. Interstitial lung disease in dermatomyositis: Clinicopathological study
23. Interstitial pneumonitis in dermatomyositis
24. Malignancy and interstitial pneumonitis as fatal complications in dermatomyositis
25. Interstitial lung disease in association with polymyositis-dermatomyositis: Long-term follow-up CT evaluation in seven patients
26. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis
27. A computer assisted analysis of 153 patients with polymyositis and dermatomyositis
28. Fibrosing alveolitis in polymyositis: A review of histologically confirmed cases
29. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis
30. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis
31. Management of fibrosing alveolitis with polymyositis dermatomyositis
32. Pulmonary fibrosis masking polymyositis. Remission with corticosteroid therapy
33. Dermatomyositis and pulmonary fibrosis associated with anti-Jo-1 antibody
34. Dermatomyositis with fibrosing alveolitis: Response to treatment with cyclophosphamide
35. Dermatomyositis with lung involvement, successfully treated with azathioprine
36. Pulmonary capillaritis and diffuse alveolar hemorrhage. A primary manifestation of polymyositis
37. Interstitial lung diseases: Current concepts of pathogenesis, staging, and therapy
38. Anti-Jo-1 antibody: A marker for myositis with interstitial lung disease
39. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody
40. Anti-KS: Identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease
41. Autoantibodies to glycyl-transfer RNA synthetase in myositis. Association with dermatomyositis and immunologic heterogeneity
42. Antibody to Jo-1 in polymyositis/dermatomyositis: Association with interstitial pulmonary disease
43. Adult onset polymyositis/dermatomyositis: An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature
44. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups
45. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes
46. Myositis autoantibody inhibits histidyl-tRNA-synthetase: A model for autoimmunity
47. Anti-Jo-1 antibodies in polymyositis or dermatomyositis: Evaluation by Elisa using recombinant fusion protein Jo-1 as antigen
48. Update on myositis-specific and myositis-associated autoantibodies
49. Antibodies to glycyltransfer RNA synthetase in patients with myositis and interstitial lung disease
50. The Jo-1 antibody system in myositis: Relationships to clinical features and HLA
51. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases: A marker for a subset of polymyositis with interstitial pulmonary fibrosis
52. Polymyositis and pulmonary fibrosis associated with anti-PL-7 antibody
53. Myositis and interstitial lung disease associated with autoantibody to a transfer RNA-related protein Wa
54. Antibodies to endothelial cells in dermatomyositis: Association with interstitial lung disease
55. Elevation of cytokeratin 19 fragment in patients with interstitial pneumonia associated with polymyositis/dermatomyositis
56. Detection of anti-Adam 10 antibody in serum of a patient with pulmonary fibrosis associated with dermatomyositis
57. Investigation of EB virus and cytomegalovirus in rapidly progressive interstitial pneumonitis in polymyositis/dermatomyositis by in situ hybridization and polymerase chain reaction
58. Dermatomyositis: Electron microscopic, immunologic and tissue culture studies of paramyxovirus-like inclusions
59. Autoantibodies are anti-idiotype antibodies to antiviral antibodies
60. Polymyositis, cranial neuropathy, autoimmune hepatitis, and hepatitis C
61. Association of HLA class I and class II alleles with myositis in Japanese patients
62. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies
63. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy
64. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: A tale of two loci
65. Update on the genetics of the idiopathic inflammatory myopathies
66. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis
67. Cyclosporine treatment for polymyositis/dermatomyositis: Is it possible to rescue the deteriorating cases with interstitial pneumonitis?
68. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy
69. Clinical features of polymyositis/dermatomyositis with steroid-resistant interstitial lung disease
70. Pulmonary involvement in polymyositis: Report of a case with response to corticosteroid therapy
71. Digital clubbing associated with polymyositis and interstitial lung disease
72. Use of sequential DTPA clearance and high resolution computerized tomography in monitoring interstitial lung disease in dermatomyositis
73. Pulmonary involvement in polymyositis and dermatomyositis: Sequential evaluation with CT
74. Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis
75. Exercise limitation in patients with polymyositis
76. Atteinte pulmonaire des dermato-polymyosites: Intérêt du lavage broncho-alvéolaire
77. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage
78. Atteinte pulmonaire au cours de la sclérodermie systémique. Partie 1. Pneumopathie interstitielle chronique fibrosante
79. Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum
80. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease
81. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis
82. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis
83. Nonspecific interstitial pneumonia/fibrosis: Histologic features and clinical significance
84. Idiopathic nonspecific interstitial pneumonia: Prognostic significance of cellular and fibrosing patterns: Survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia
85. Non specific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients
86. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification
87. Dermatomyosite, fibrose pulmonaire léthale, nécroses cutanées
88. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis
89. Serum KL-6 in adult patients with polymyositis and dermatomyositis
90. Current approach to the treatment of polymyositis and dermatomyositis
91. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases
92. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis
93. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis
94. Tacrolimus in refractory polymyositis with interstitial lung disease
95. Efficacité du traitement par immunoglobulines polyvalentes à forte dose au cours d'une polymyosite avec atteinte respiratoire sévère